Table 2.

Summary of results of primary and secondary efficacy measures (FAS)

Measures	Evocalcet (n = 199)	Cinacalcet (n = 196)	Difference between groups (evocalcet − cinacalcet), P-value
Mean percentage change in iPTH (95% CI)	−34.7 (−40.8, −28.5)	−30.2 (−36.3, −24.2)	−4.4 (−13.1, 4.3), 0.000
Target iPTH level ≥30% (percentage change ≤ −30%) from baseline (95% CI)	67.3 (60.2, 74.5)	58.7 (51.2, 66.2)	8.6 (−1.8, 19.1), 0.000
Target iPTH level (≥150 pg/ml and ≤300 pg/ml) (95% CI)	33.8 (26.8, 40.8)	34.1 (26.9, 41.2)	−0.2 (−10.2, 9.8), 0.003

CI, confidence interval; FAS, full analysis set, PTH, parathyroid hormone.

95% CI values were derived by t statistic. The noninferiority margin was 15%. P-values were calculated by t-test.